Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.62 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843224 | 1.00 | CHRNA7 (0.62) | CHRNA7SMYD3USP30HTR3EHTR3B | |
| SCHEMBL844079 | 0.86 | CHRNA7 (0.65) | CHRNA7SMYD3HTR3EHTR3BHTR3A | |
| SCHEMBL844080 | 0.86 | CHRNA7 (0.65) | CHRNA7SMYD3HTR3EHTR3BHTR3A | |
| SCHEMBL6008210 | 0.84 | CHRNA7 (0.52) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL842719 | 0.81 | CHRNA7 (0.64) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL842718 | 0.81 | CHRNA7 (0.64) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL844001 | 0.81 | CHRNA7 (0.58) | CHRNA7SMYD3USP30HTR3EHTR3B | |
| SCHEMBL844000 | 0.81 | CHRNA7 (0.58) | CHRNA7SMYD3USP30HTR3EHTR3B | |
| SCHEMBL843727 | 0.81 | CHRNA7 (0.71) | CHRNA7SMYD3USP30HTR3EHTR3B | |
| SCHEMBL843728 | 0.81 | CHRNA7 (0.71) | CHRNA7SMYD3USP30HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | claimed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | CHRNA7 5/4885SMYD3 3529/4885USP30 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.